BBL
ALNY icon

Beck Bode LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Beck Bode LLC’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-56,017
Closed -$13.2M – 105
2024
Q4 		$13.2M Buy
+56,017
New +$14.7M 2.41% 24

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Beck Bode LLC's ALNY Position: Q1 2025 in Review

Beck Bode LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 56,017 shares — an estimated $13.2M sold.

Beck Bode LLC first reported a position in ALNY in Q4 2024 and held it in 1 quarter. The position peaked at $13.2M in Q4 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Beck Bode LLC reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Beck Bode LLC sold 56,017 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $13.2M.
  • Beck Bode LLC first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Beck Bode LLC's Alnylam Pharmaceuticals position peaked at $13.2M in Q4 2024.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Beck Bode LLC's 13F filing for Q1 2025, filed 14 May 2025.